Featuring perspectives from Dr Heather Wakelee, including the following topics:

• Introduction (0:00)
• Cases: A man in his late 50s with metastatic carcinoma of the lung, no actionable genomic alteration (AGA), PD-L1-negative, and a man in his early 60s with metastatic squamous cell carcinoma of the lung, PD-L1-negative — Brian P Mulherin, MD and Taral Patel, MD (8:08)
• Case: A man in his late 60s presenting with metastatic adenocarcinoma of the lung, multiple bone metastases, no AGA; PD-L1 20%; enrolled on ECOG-EA5163 — Priya Rudolph, MD, PhD (21:45)
• Current and Emerging Immunotherapeutic Strategies for Metastatic Non-Small Cell Lung Cancer (mNSCLC) (30:55)
• Case: An African American man in his early 60s with 6.2-cm squamous cell carcinoma of right upper lung receives neoadjuvant treatment as per CheckMate 816 — Dr Rudolph (39:16)
• Case: A man in his late 60s with pT2aN0 invasive adenocarcinoma of the right lower lung, no AGA; PD-L1 5% — Zanetta S Lamar, MD (44:57)
• Antibody-Drug Conjugates and Other Management Approaches for mNSCLC without AGAs (48:51)
• Case: A woman in her early 60s diagnosed in 2014 with metastatic adenocarcinoma of the lung treated on ECOG 5508 (carboplatin/paclitaxel/bevacizumab) receives nivolumab on disease progression — Dr Rudolph (56:35)

CME information and select publications

Featuring perspectives from Dr Priyanka Sharma and Dr Sara M Tolaney, including the following topics:

• Introduction: Metastatic Triple-Negative Breast Cancer (mTNBC) — The Patient Perspective (0:00)
• Selection and Sequencing of Antibody-Drug Conjugates (5:09)
• Dosing and Tolerability of Sacituzumab Govitecan; Use of Anthracyclines (14:39)
• Case: A woman in her early 60s with relapsed TNBC (HER2 2+) who experiences disease progression on T-DXd (Grade 2 interstitial lung disease) and receives sacituzumab govitecan — Shaachi Gupta, MD, MPH (22:04)
• Discussing Palliative and End-of-Life Care (32:40)
• PARP Inhibitors for TNBC with Somatic versus Germline Mutations; Cytopenias with PARP Inhibitors (37:53)
• The “Art of Oncology” — Building Trust with Patients and Family Members (45:05)
• Case: A woman in her mid 60s with recurrent TNBC with extensive chest wall involvement — Dr Gupta (48:44)
• Case: A man in his mid 40s with multiregimen-refractory AR-positive TNBC with an ERBB2 exon 20 insertion mutation — Dr Gupta (52:53)

CME information and select publications

Featuring perspectives from Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile M Shammo, including the following topics:

Introduction: Paroxysmal Nocturnal Hemoglobinuria (PNH) and the General Medical Oncologist

• Diagnosis of and myths and misperceptions about PNH (0:00)

Overview — Biology and Pathophysiology

• Role of complement activation in PNH; classification and clinical presentation (7:00)
• PNH treatments and their complement targets (21:37)

Current Management Approaches

• Mechanistic similarities and differences between crovalimab and other available C5 inhibitors; potential practical advantages of crovalimab (24:56)
• Timing for initiation of treatment for PNH (32:08)
• Management of clinically significant extravascular hemolysis and residual anemia in patients with PNH receiving C5 inhibitor therapy (43:08)
• Risk of evolution to aplastic anemia or myeloid malignancy (45:54)
• Clinical trial database establishing the efficacy and safety of the C5 complement inhibitors eculizumab and ravulizumab for PNH (48:47)
• Activity and safety of and clinical experience with crovalimab (53:03)
• Monitoring and management of PNH in pregnant patients (58:37)

Case Presentations

• Case: A woman in her early 30s who receives a new diagnosis of classical PNH with symptomatic anemia — Dr Gerber (1:03:44)
• Case: A man in his early 30s with PNH initially treated with eculizumab who is transitioned to ravulizumab — Dr Koprivnikar (1:17:32)
• Case: A woman in her early 50s with a remote history of aplastic anemia — Dr Gerber (1:32:24)
• Case: A woman in her late 20s with PNH receiving active C5 inhibitor therapy who wishes to discuss alternative treatment options — Dr Koprivnikar (1:38:00)

CME information and select publications